Market Assessment, Alzheimer's Disease Access and Reimbursement EU5 2017 Report

Alzheimer’s disease (AD) is a chronic neurodegenerative condition widely recognized as a global health crisis; as the general population ages and AD prevalence grows, the need for drugs to treat, delay, or stop the disease is paramount. While current therapies used to treat AD are generically available in Europe, the next five years look set to bring several premium-priced new brands addressing the cognitive as well as the behavioral symptoms of AD. This research examines the current impact of payer policy on prescribing and probes how neurologists and cost-conscious European payers will react to novel agents that, while innovative, will drive up healthcare costs considerably.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Alzheimer’s Disease | Access and Reimbursement | EU5 | 2017

Related Market Assessment Reports

Alzheimer’s Disease – Landscape & Forecast – Disease Landscape & Forecast

Alzheimer’s Disease | Disease Landscape & Forecast | G7 | 2022

Alzheimer’s Disease – Access & Reimbursement – Detailed, Expanded Analysis (US)

Alzheimer’s Disease | Treatment Algorithms | Claims Data Analysis | US | 2022

Alzheimer’s Disease – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms – Claims Data Analysis (US)